Treating myopic foveoschisis
Treating myopic foveoschisis
Vitreous cortex removal and internal limiting membrane (ILM) peeling could be critical in treating persistent myopic foveoschisis (MF), according to the results of a study published in the American Journal of Ophthalmology.
Kaori Sayanagi, Yasushi Ikuno and Yasuo Tano from Osaka University Medical School, Osaka, Japan, examined two highly myopic eyes of two patients with persistent MF after primary vitrectomy and gas tamponade. Both were then treated with pars plana vitrectomy, residual vitreous cortex removal, ILM peeling and long-term gas tamponade.In both cases total foveal reattachment was achieved in addition to improvements in best-corrected visual acuity.
The authors concluded that re-operation with vitreous cortex removal and ILM peeling could benefit patients with MF after their primary surgery. It also indicates that both treatments, if used in the first instance, could prevent the need for any re-operation at all.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
August 5th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction
